A 48-year-old woman with benign prostatic hyperplasia is prescribed an alpha-1 adrenergic antagonist. Which of the following is the most common tissue site where alpha-1 receptor blockade produces its therapeutic effect in this condition?

Explanation

## Alpha-1 Adrenergic Antagonism in Benign Prostatic Hyperplasia ### Anatomical Basis of Therapeutic Effect **Key Point:** Alpha-1 adrenergic receptors are abundantly expressed in the **smooth muscle of the prostatic urethra and prostatic stroma**. These are the primary sites where alpha-1 antagonists (e.g., tamsulosin, doxazosin) exert their therapeutic effect in BPH. **High-Yield:** The mechanism of symptom relief in BPH involves: 1. **Smooth muscle relaxation in the prostate:** - α₁-receptors mediate tonic contraction of prostatic smooth muscle - Blockade causes relaxation of the prostatic capsule and urethral smooth muscle - Results in decreased urethral resistance and improved urine flow 2. **Site-specific density:** - Prostatic urethra: **highest concentration** of α₁-receptors in the lower urinary tract - Prostatic stroma: rich in α₁A-receptor subtype - Detrusor muscle: minimal α₁-receptor expression (primarily M₃ muscarinic) ### Why This Is the "Most Common" Therapeutic Site Alpha-1 antagonists relieve **lower urinary tract symptoms (LUTS)** in BPH by relaxing the tissue with the **highest density of functional α₁-receptors**. This is the primary mechanism of symptom improvement in 60–70% of BPH patients. **Clinical Pearl:** Selective α₁A-antagonists (e.g., tamsulosin) preferentially block receptors in the prostate and urethra while sparing α₁B-receptors in blood vessels, resulting in fewer systemic hypotensive effects compared to non-selective agents (e.g., doxazosin, terazosin). **Mnemonic:** **PUSS** — **P**rostatic urethra, **U**rethral smooth muscle, **S**troma, **S**mooth muscle relaxation = symptom relief. ### Comparison of Alpha-1 Receptor Distribution in Lower Urinary Tract | Tissue Site | α₁-Receptor Density | Functional Role | Effect of Blockade | |-------------|-------------------|-----------------|-------------------| | Prostatic urethra | **Very high** | Tonic contraction | ↓ Urethral resistance | | Prostatic stroma | **High** | Smooth muscle tone | Relaxation | | Detrusor muscle | Low | Minimal role | Minimal effect | | Trigone | Low | Minimal role | Minimal effect | | Bladder neck | Moderate | Closure mechanism | Slight effect | ### Why Detrusor Muscle Is Not the Answer The detrusor muscle is primarily innervated by **parasympathetic M₃ muscarinic receptors** and contains few functional α₁-receptors. Blockade of the detrusor would not explain the therapeutic benefit in BPH. In fact, some patients experience urinary retention if detrusor function is compromised, but this is not the mechanism of alpha-1 antagonist action. [cite:Harrison 21e Ch 297]